Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
Renalyx will continue operating as an independent unit within the group
RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US
Clinical trials found that 77% of patients went into remission after receiving obe-cel
A key highlight will be Brenntag’s qualified amino acids portfolio
Paxton alleges the companies marketed Plavix as a reliable defense against heart attacks, strokes, and blood clots while failing to disclose evidence that the drug could be ineffective or virtually useless for many people
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
_256_384.png)
India presents one of the world’s largest untapped opportunities for neurovascular screening
Subscribe To Our Newsletter & Stay Updated
